There is an ongoing investigation in Europe about thromboembolic events. They are thought to be potentially related to some lots, but more needs to be found.
At this point, there is no concern in Canada about the potential risk for thromboembolic adverse events with the AstraZeneca vaccine. I could add, as a complementary piece of information, that in the U.K., where 11 million doses of the AstraZeneca vaccine were administered, there were no safety signals of thromboembolic events that were identified.